Background Positron emission tomography (PET) is a molecular imaging technology that
enables in vivo quantification of metabolic activity or receptor density, among other …

Clinical trials aiming to develop disease-altering drugs for Alzheimer's disease (AD), a
neurodegenerative disorder with devastating consequences, are failing at an alarming rate …

Over the past 35 years or so, PET brain imaging has allowed powerful and unique insights
into brain function under normal conditions and in disease states. Initially, as PET …

The use of PET to examine the behavioral, therapeutic and toxic properties of drugs and
substances of abuse is emerging as a powerful new scientific tool. PET provides a new …

Development of a new drug faces multi-faceted sequences in the pipeline. Once a drug
candidate is identified, evaluation process can be accelerated by in vivo noninvasive …

Recent advances in noninvasive imaging modalities have opened endless opportunities for
molecular diagnostic and therapeutic procedures. The term “molecular imaging” is broadly …

Positron emission tomography (PET) is a powerful tool for imaging biological processes in
the central nervous system (CNS). Designing PET radiotracers capable of crossing the …

Positron emission tomography (PET) is a molecular imaging modality that enables in vivo
exploration of metabolic processes and especially the pharmacology of neuroreceptors. G …

Advances in nuclear medicine have revolutionized our ability to accurately diagnose
patients with a wide array of neurologic pathologies and provide appropriate therapy. The …

The increasing availability of PET imaging in nuclear medicine expands the armamentarium
of clinical and research tools for improving diagnosis and treatment of neuropsychiatric …